The world of weight loss is undergoing a quiet revolution, and it's all thanks to a class of drugs known as GLP-1s. These glucagon-like peptide-1 drugs have gone from being a diabetes treatment to a weight-loss wonder, and now they're changing the game for millions of Americans. But what makes this trend so fascinating, and what does it mean for the future of healthcare? Let's dive in and explore the rise of the Ozempic nation, and why this is more than just a fad diet.
A New Kind of Diet
In the past two years, the use of GLP-1 drugs like Ozempic and Wegovy has nearly quadrupled in the US. This is a staggering statistic, and it's not just a passing trend. The Gallup survey reveals that 11% of Americans are now taking these drugs for weight loss, up from just 3% in 2024. But what's even more interesting is the broader impact of this trend. The national obesity rate has been steadily declining, and the diabetes rate has held steady after years of increase. This is a significant shift, and it's all thanks to the power of GLP-1s.
From Diabetes Drug to Weight-Loss Wonder
GLP-1s work by mimicking the hormones naturally released by the gut after eating, helping to regulate blood sugar, appetite, and digestion. The first drug in this class was approved over two decades ago to treat type 2 diabetes, but it wasn't until 2021 that GLP-1s exploded in popularity. That year, the FDA approved Novo Nordisk's semaglutide-based drug Wegovy as an obesity treatment, and the rest is history. Since then, the market has expanded with new players like Eli Lilly's tirzepatide-based Zepbound and Mounjaro for diabetes.
The Next Frontier of GLP-1s
The reach of GLP-1s is only expected to grow, as more convenient and potentially more powerful versions hit the market. In December 2025, the FDA approved a daily pill version of Wegovy, giving needle-averse patients the first oral GLP-1 option cleared for obesity treatment. Then in April, the agency approved another oral weight-loss contender from Eli Lilly: orforglipron, sold under the brand name Foundayo. The next wave is already on the horizon, with Eli Lilly's once-weekly injectable retatrutide expected to seek FDA approval this year.
Expanding Uses
The drugs' expanding résumé could also fuel the next wave of growth, as researchers explore uses far beyond weight loss and diabetes. Already, Wegovy's label has expanded to include treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease, in adults with moderate to advanced liver fibrosis. The drug is also approved to reduce the risk of major cardiovascular events, including heart attacks and strokes, in adults with obesity and established heart disease. Zepbound, meanwhile, became the first and only FDA-approved medication for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
The Dark Side of GLP-1s
But the drugs aren't without drawbacks. GLP-1s have been linked to a range of side effects, with the most common including gastrointestinal problems such as nausea, vomiting, diarrhea, and constipation. For some patients, complications can be serious, with rare but severe risks including pancreatitis, gallbladder disease, bowel obstruction, stomach paralysis, acute kidney injury, and vision problems. Patients have also reported challenges tied to rapid weight loss, including loose or sagging skin, muscle loss, and the return or emergence of eating disorder symptoms.
The Future of GLP-1s
In my opinion, the future of GLP-1s is bright, but it's not without its challenges. The drugs have the potential to revolutionize the way we approach weight loss and diabetes, but they also come with a range of side effects that need to be carefully managed. As more convenient and potentially more powerful versions hit the market, we'll see a new wave of growth, but we'll also need to be mindful of the potential risks. Personally, I think that the next frontier of GLP-1s will be in the treatment of neurodegenerative diseases like Alzheimer's and chronic joint pain. What many people don't realize is that GLP-1s have already shown promise in these areas, and we may see more breakthroughs in the coming years.
Conclusion
The rise of the Ozempic nation is a fascinating development in the world of healthcare. It's a testament to the power of innovation and the potential for drugs to transform our lives. But it's also a reminder that with great power comes great responsibility. As we continue to explore the potential of GLP-1s, we must also be mindful of the potential risks and side effects. The future of GLP-1s is bright, but it's not without its challenges. From my perspective, the next wave of growth will be fueled by the expanding uses of these drugs, but we must also be prepared for the potential drawbacks. If you take a step back and think about it, the rise of GLP-1s is a powerful reminder of the potential for drugs to change the world, but it's also a call to action for us to be mindful of the potential risks and side effects.
